Dr. Saubermann's clinical interest is centered on taking care of adolescents and adults with Inflammatory Bowel Diseases, such as Crohn's Disease, Ulcerative Colitis, Celiac Sprue(gluten sensitive enteropathy), and microscopic /lymphocytic colitis, though he also sees patients with a variety of gast...

Faculty Appointments

Professor - Department of Medicine, Gastroenterology/Hepatology (SMD)

Professor - Department of Pediatrics, Pediatric Gastroenterology, Hepatology and Nutrition (SMD) - Joint

Credentials

Residency & Fellowship

Fellowship, Gastroenterology, Brigham & Womens Hospital. 1994 - 1998

Residency, Internal Medicine, Rhode Island Hospital. 1992 - 1994

Internship, Internal Medicine, Rhode Island Hospital. 1991 - 1992

Education

MD | UT Southwestern Medical Center (Allied Health). 1991

Awards

CCFA Executive Board and CMAC. 2010

Fellowship in American College of Gastroenterology. 2009

Chair of Education, Appointed Member. 2008

Senior Research Award
Crohn's and Colitis Foundation of America Senior Research Award 2003

Appointed Institutional Review Board Committee Member (Panel Purple, Active) 2002

Appointed Member of New England CCFA Medical Advisory Committee (Active) 2002

Broad Medical Research Program Award
Broad Foundation 2002

Appointed Institutional Review Board Committee Member (Panel Green, Active) 2001

Mentored Clinical Scientist Development Award (K08)
National Institutes of Health 1998

Physician Post-Doctoral Research Fellowship Award
Howard Hughes Medical Institute 1998

Mentored Clinical Scientist Development Award K08. 1998

Astra-Merck Advanced Research Training Award
American Digestive Health Foundation 1997

cum laude
Brandeis University 1987

Research

Dr. Saubermann is interested in the intestinal mucosal immune system, and how it is involved in Inflammatory Bowel Diseases, such as Crohn's Disease, Ulcerative Colitis, Microscopic/lymphocytic colitis, and Celiac Sprue. He has a number of projects related to inflammatory bowel disease, including cl...

Publications

Journal Articles

P047?The Crohn's Disease-Health Index (CD-HI): Development and Validation of a Novel, Disease-Specific Patient Reported Outcome Measure for Clinical Trials.

The American journal of gastroenterology.. 2021 December 1116 (Suppl 1):S12. Epub 1900 01 01.

Late-Onset Posttransplant Lymphoproliferative Disorder Results in Jejunal Stricture Managed with Endoscopic Dilation.

Park S, Miller J, Cheong J, Ullah A, Saubermann L, Decross A

Case reports in gastrointestinal medicine. 2021 2021 :5583665. Epub 08/03/2021.

Assessment of systemic genetic damage in pediatric inflammatory bowel disease.

Baig A, Avlasevich SL, Torous DK, Bemis JC, Saubermann LJ, Lovell DP, MacGregor JT, Dertinger SD

Environmental and molecular mutagenesis.. 2020 November 61 (9):901-909. Epub 08/22/2020.

Human blood PIG-A mutation and micronucleated reticulocyte flow cytometric assays: Method optimization and evaluation of intra- and inter-subject variation.

Torous DK, Avlasevich SL, Khattab MG, Baig A, Saubermann LJ, Chen Y, Bemis JC, Lovell DP, Walker VE, MacGregor JT, Dertinger SD

Environmental and molecular mutagenesis.. 2020 October 61 (8):807-819. Epub 07/27/2020.

Dextran sulfate sodium mouse model of inflammatory bowel disease evaluated for systemic genotoxicity via blood micronucleus and Pig-a gene mutation assays.

Kirby C, Baig A, Avlasevich SL, Torous DK, Tian S, Singh P, Bemis JC, Saubermann LJ, Dertinger SD

Mutagenesis.. 2020 March 2735 (2):161-167. Epub 1900 01 01.

Assessing the Validity of Adult-derived Prognostic Models for Primary Sclerosing Cholangitis Outcomes in Children.

Deneau M, Valentino P, Mack C, Alqoaer K, Amin M, Amir A, Aumar M, Auth M, Broderick A, DiGuglielmo M, Draijer LG, El-Matary W, Ferrari F, Furuya K, Gottrand F, Gupta N, Homan M, Jensen MK, Kamath BM, Kim KM, Kolho KL, Koot BG, Iorio R, Martinez M, Miloh T, Mohan P, Palle S, Papadopoulou A, Ricciuto A, Saubermann L, Sathya P, Shteyer E, Smolka V, Tanaka A, Varier R, Venkat V, Vitola B, Woynarowski M, Guthery S

Journal of pediatric gastroenterology and nutrition.. 2020 January 70 (1):e12-e17. Epub 1900 01 01.

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.

Sands BE, Sandborn WJ, Panaccione R, O'Brien CD, Zhang H, Johanns J, Adedokun OJ, Li K, Peyrin-Biroulet L, Van Assche, Danese S, Targan S, Abreu MT, Hisamatsu T, Szapary P, Marano C

The New England journal of medicine.. 2019 September 26381 (13):1201-1214. Epub 1900 01 01.

Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis: Predictors of Gamma Glutamyltransferase Normalization and Favorable Clinical Course.

Deneau M, Perito E, Ricciuto A, Gupta N, Kamath BM, Palle S, Vitola B, Smolka V, Ferrari F, Amir AZ, Miloh T, Papadopoulou A, Mohan P, Mack C, Kolho KL, Iorio R, El-Matary W, Venkat V, Chan A, Saubermann L, Valentino PL, Shah U, Miethke A, Lin H, Jensen MK

The Journal of pediatrics.. 2019 June 209 :92-96.e1. Epub 03/14/2019.

Unexpectedly High Prevalence of Cystoisospora belli Infection in Acalculous Gallbladders of Immunocompetent Patients.

Noor M, Katzman PJ, Huber AR, Findeis-Hosey JJ, Whitney-Miller C, Gonzalez RS, Zhou Z, N'kodia HD, Skonick K, Abell RL, Saubermann LJ, Lamps LW, Drage MG

American journal of clinical pathology.. 2019 January 1151 (1):100-107. Epub 1900 01 01.

Gamma Glutamyltransferase Reduction Is Associated With Favorable Outcomes in Pediatric Primary Sclerosing Cholangitis.

Deneau MR, Mack C, Abdou R, Amin M, Amir A, Auth M, Bazerbachi F, Marie Broderick A, Chan A, DiGuglielmo M, El-Matary W, El-Youssef M, Ferrari F, Furuya KN, Gottrand F, Gupta N, Homan M, Jensen MK, Kamath BM, Mo Kim K, Kolho KL, Konidari A, Koot B, Iorio R, Martinez M, Mohan P, Palle S, Papadopoulou A, Ricciuto A, Saubermann L, Sathya P, Shteyer E, Smolka V, Tanaka A, Valentino PL, Varier R, Venkat V, Vitola B, Vos MB, Woynarowski M, Yap J, Miloh T

Hepatology communications.. 2018 November 2 (11):1369-1378. Epub 09/25/2018.

The natural history of primary sclerosing cholangitis in 781 children: A multicenter, international collaboration.

Deneau MR, El-Matary W, Valentino PL, Abdou R, Alqoaer K, Amin M, Amir AZ, Auth M, Bazerbachi F, Broderick A, Chan A, Cotter J, Doan S, El-Youssef M, Ferrari F, Furuya KN, Gottrand M, Gottrand F, Gupta N, Homan M, Kamath BM, Kim KM, Kolho KL, Konidari A, Koot B, Iorio R, Ledder O, Mack C, Martinez M, Miloh T, Mohan P, O'Cathain N, Papadopoulou A, Ricciuto A, Saubermann L, Sathya P, Shteyer E, Smolka V, Tanaka A, Varier R, Venkat V, Vitola B, Vos MB, Woynarowski M, Yap J, Jensen MK

Hepatology : official journal of the American Association for the Study of Liver Diseases.. 2017 August 66 (2):518-527. Epub 06/26/2017.

Hepatic Issues and Complications Associated With Inflammatory Bowel Disease: A Clinical Report From the NASPGHAN Inflammatory Bowel Disease and Hepatology Committees.

Saubermann LJ, Deneau M, Falcone RA, Murray KF, Ali S, Kohli R, Ekong UD, Valentino PL, Grossman AB, Rand EB, Jonas MM, Saeed SA, Kamath BM

Journal of pediatric gastroenterology and nutrition.. 2017 April 64 (4):639-652. Epub 1900 01 01.

Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.

Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV, Dieleman LA, Katz S, Rutgeerts P,

The New England journal of medicine.. 2016 November 17375 (20):1946-1960. Epub 1900 01 01.

Sustained improvement in health-related quality of life measures in patients with inflammatory bowel disease receiving prolonged anti-tumor necrosis factor therapy.

Sherman M, Tsynman DN, Kim A, Arora J, Pietras T, Messing S, St Hilaire L, Yoon S, Decross A, Shah A, Saubermann L

Journal of digestive diseases.. 2014 April 15 (4):174-9. Epub 1900 01 01.

Understanding IBD

Saubermann, Lawrence J.

CAP PC. 2014; : 4 & 8.

Colorectal cancer in IBD patients.

Stormont JM, Shah AN, Sharma AK, Saubermann LJ, Farmer RG

The American journal of gastroenterology.. 2013 September 108 (9):1535. Epub 1900 01 01.

Vedolizumab as induction and maintenance therapy for Crohn's disease.

Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A,

The New England journal of medicine.. 2013 August 22369 (8):711-21. Epub 1900 01 01.

Neither direct nor developmental exposure to bisphenol A alters the severity of experimental inflammatory colitis in mice.

Roy A, Gaylo A, Cao W, Saubermann LJ, Lawrence BP

Journal of immunotoxicology.. 2013 10 (4):334-40. Epub 01/03/2013.

A 16-year-old girl with perianal skin tags.

Mohanty PH, Sood V, Saubermann LJ

Pediatric annals.. 2012 June 41 (6):10-2. Epub 1900 01 01.

Mitigation effect of an FGF-2 peptide on acute gastrointestinal syndrome after high-dose ionizing radiation.

Zhang L, Sun W, Wang J, Zhang M, Yang S, Tian Y, Vidyasagar S, Peña LA, Zhang K, Cao Y, Yin L, Wang W, Zhang L, Schaefer KL, Saubermann LJ, Swarts SG, Fenton BM, Keng PC, Okunieff P

International journal of radiation oncology, biology, physics.. 2010 May 177 (1):261-8. Epub 1900 01 01.

PPAR gamma suppresses early phase but increases late phase production of IL-8 in TNFa-stimulated intestinal epithelial cells

Schaefer KL; Harris G; Jasalavich CA; Morales VM; Saubermann LJ.

To be submitted. 2010; .

Characterization of K-ras gene mutations in association with mucinous hypersecretion in intraductal papillary-mucinous neoplasms.

Kobayashi N, Inamori M, Fujita K, Fujisawa T, Fujisawa N, Takahashi H, Yoneda M, Abe Y, Kawamura H, Shimamura T, Kirikoshi H, Kubota K, Sakaguchi T, Saito S, Saubermann LJ, Nakajima A

Journal of hepato-biliary-pancreatic surgery.. 2008 15 (2):169-77. Epub 04/06/2008.

Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease.

Kugathasan S, Saubermann LJ, Smith L, Kou D, Itoh J, Binion DG, Levine AD, Blumberg RS, Fiocchi C

Gut.. 2007 December 56 (12):1696-705. Epub 08/06/2007.

PPARgamma inhibitors reduce tubulin protein levels by a PPARgamma, PPARdelta and proteasome-independent mechanism, resulting in cell cycle arrest, apoptosis and reduced metastasis of colorectal carcinoma cells.

Schaefer KL, Takahashi H, Morales VM, Harris G, Barton S, Osawa E, Nakajima A, Saubermann LJ

International journal of cancer.. 2007 February 1120 (3):702-13. Epub 1900 01 01.

Repertoire of the alpha beta T-cell receptor in the intestine.

Probert CS, Saubermann LJ, Balk S, Blumberg RS

Immunological reviews.. 2007 February 215 :215-25. Epub 1900 01 01.

Inhibition of peroxisome proliferator-activated receptor gamma activity in esophageal carcinoma cells results in a drastic decrease of invasive properties.

Takahashi H, Fujita K, Fujisawa T, Yonemitsu K, Tomimoto A, Ikeda I, Yoneda M, Masuda T, Schaefer K, Saubermann LJ, Shimamura T, Saitoh S, Tachibana M, Wada K, Nakagama H, Nakajima A

Cancer science.. 2006 September 97 (9):854-60. Epub 06/29/2006.

Anti-Saccharomyces cerevisiae antibodies are associated with the development of postoperative fistulas following ileal pouch-anal anastomosis.

Dendrinos KG, Becker JM, Stucchi AF, Saubermann LJ, LaMorte W, Farraye FA

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract.. 2006 10 (7):1060-4. Epub 1900 01 01.

Peroxisome proliferator-activated receptor gamma inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells.

Schaefer KL, Wada K, Takahashi H, Matsuhashi N, Ohnishi S, Wolfe MM, Turner JR, Nakajima A, Borkan SC, Saubermann LJ

Cancer research.. 2005 March 1565 (6):2251-9. Epub 1900 01 01.

Intestinal antiinflammatory effects of thiazolidenedione peroxisome proliferator-activated receptor-gamma ligands on T helper type 1 chemokine regulation include nontranscriptional control mechanisms.

Schaefer KL, Denevich S, Ma C, Cooley SR, Nakajima A, Wada K, Schlezinger J, Sherr D, Saubermann LJ

Inflammatory bowel diseases.. 2005 March 11 (3):244-52. Epub 1900 01 01.

Protective effect of endogenous PPARgamma against acute gastric mucosal lesions associated with ischemia-reperfusion.

Wada K, Nakajima A, Takahashi H, Yoneda M, Fujisawa N, Ohsawa E, Kadowaki T, Kubota N, Terauchi Y, Matsuhashi N, Saubermann LJ, Nakajima N, Blumberg RS

American journal of physiology. Gastrointestinal and liver physiology.. 2004 August 287 (2):G452-8. Epub 1900 01 01.

Gene expression profile after peroxisome proliferator activator receptor-gamma ligand administration in dextran sodium sulfate mice.

Nakajima A, Wada K, Katayama K, Saubermann L, Osawa E, Nagase H, Ueno N, Matsuhashi N, Aburatani H

Journal of gastroenterology.. 2002 November 37 Suppl 14 :62-6. Epub 1900 01 01.

Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis.

Saubermann LJ, Nakajima A, Wada K, Zhao S, Terauchi Y, Kadowaki T, Aburatani H, Matsuhashi N, Nagai R, Blumberg RS

Inflammatory bowel diseases.. 2002 September 8 (5):330-9. Epub 1900 01 01.

Protective Effects of PPARy in Gastrointestinal Mucosal Injuries.

Matsuhashi, N.; Nakajima, A.; Wada, K.; Miki, H.; Saubermann, LJ.; Kubota, N.; Terauchi, Y.; Kadowaki, T.; Nagai, R.; Blumberg, RS.

Immunology. 2002; 4: 227-233.

Prevalence of an ulcerative colitis-associated CD8+ T cell receptor beta-chain CDR3-region motif and its association with disease activity.

Probert CS, Chott A, Saubermann LJ, Stevens AC, Balk SP, Blumberg RS

Journal of clinical immunology.. 2001 March 21 (2):126-34. Epub 1900 01 01.

Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury.

Nakajima A, Wada K, Miki H, Kubota N, Nakajima N, Terauchi Y, Ohnishi S, Saubermann LJ, Kadowaki T, Blumberg RS, Nagai R, Matsuhashi N

Gastroenterology.. 2001 February 120 (2):460-9. Epub 1900 01 01.

pANCA--is this your final answer?

Saubermann LJ

Inflammatory bowel diseases.. 2000 November 6 (4):332-3. Epub 1900 01 01.

Limited CD4 T-cell diversity associated with colitis in T-cell receptor alpha mutant mice requires a T helper 2 environment.

Mizoguchi A, Mizoguchi E, Saubermann LJ, Higaki K, Blumberg RS, Bhan AK

Gastroenterology.. 2000 October 119 (4):983-95. Epub 1900 01 01.

Activation of natural killer T cells by alpha-galactosylceramide in the presence of CD1d provides protection against colitis in mice.

Saubermann LJ, Beck P, De Jong YP, Pitman RS, Ryan MS, Kim HS, Exley M, Snapper S, Balk SP, Hagen SJ, Kanauchi O, Motoki K, Sakai T, Terhorst C, Koezuka Y, Podolsky DK, Blumberg RS

Gastroenterology.. 2000 July 119 (1):119-28. Epub 1900 01 01.

Fractalkine is an epithelial and endothelial cell-derived chemoattractant for intraepithelial lymphocytes in the small intestinal mucosa.

Muehlhoefer A, Saubermann LJ, Gu X, Luedtke-Heckenkamp K, Xavier R, Blumberg RS, Podolsky DK, MacDermott RP, Reinecker HC

The Journal of immunology : official journal of the American Association of Immunologists.. 2000 March 15164 (6):3368-76. Epub 1900 01 01.

Animal models of mucosal inflammation and their relation to human inflammatory bowel disease.

Blumberg RS, Saubermann LJ, Strober W

Current opinion in immunology.. 1999 December 11 (6):648-56. Epub 1900 01 01.

Antigen presentation by intestinal epithelial cells.

Blumberg RS, Lencer WI, Zhu X, Kim HS, Claypool S, Balk SP, Saubermann LJ, Colgan SP

Immunology letters.. 1999 June 1569 (1):7-11. Epub 1900 01 01.

Mesalamine: safe at first look.

Saubermann LJ, Wolf JL

Inflammatory bowel diseases.. 1999 May 5 (2):148-9. Epub 1900 01 01.

Evidence of T cell receptor beta-chain patterns in inflammatory and noninflammatory bowel disease states.

Saubermann LJ, Probert CS, Christ AD, Chott A, Turner JR, Stevens AC, Balk SP, Blumberg RS

The American journal of physiology.. 1999 March 276 (3):G613-21. Epub 1900 01 01.

Duodenal variceal bleeding treated with a combination of endoscopic ligation and sclerotherapy.

Omata F, Itoh T, Shibayama Y, Ide H, Takahashi H, Ueno F, Saubermann LJ, Matsuzaki S

Endoscopy.. 1998 June 30 (5):S62-3. Epub 1900 01 01.

T-cell receptor usage in the intestine.

Probert CS, Aitken EW, Saubermann LJ, Balk SP, Blumberg RS

Chemical immunology.. 1998 71 :27-39. Epub 1900 01 01.

Analysis of human common bile duct-associated T cells: evidence for oligoclonality, T cell clonal persistence, and epithelial cell recognition.

Probert CS, Christ AD, Saubermann LJ, Turner JR, Chott A, Carr-Locke D, Balk SP, Blumberg RS

The Journal of immunology : official journal of the American Association of Immunologists.. 1997 February 15158 (4):1941-8. Epub 1900 01 01.

Persistent clonal expansions of peripheral blood CD4+ lymphocytes in chronic inflammatory bowel disease.

Probert CS, Chott A, Turner JR, Saubermann LJ, Stevens AC, Bodinaku K, Elson CO, Balk SP, Blumberg RS

The Journal of immunology : official journal of the American Association of Immunologists.. 1996 October 1157 (7):3183-91. Epub 1900 01 01.

Sequence of an intestinal cDNA encoding human gastric inhibitory polypeptide precursor.

Takeda J, Seino Y, Tanaka K, Fukumoto H, Kayano T, Takahashi H, Mitani T, Kurono M, Suzuki T, Tobe T

Proceedings of the National Academy of Sciences of the United States of America.. 1987 October 84 (20):7005-8. Epub 1900 01 01.

Books

Therapies of Digestive Disorders, second edition (2006)

Chapter: Ulcerative Colitis

Cecil Essentials of Medicine (2003)

Chapter: Inflammatory Bowel Disease

Immunological Aspects of Gastroenterology (2000)

Chapter: Molecular Immunology of Mucosal T Cells

Molecular Immunology of Mucosal T Cells (2000)

Chapter: Immunological Aspects of Gastroenterology

Inflammatory Bowel Disease: A Guide for Patients and Their Families (1998)

Chapter: Reproduction and Inflammatory Bowel Disese.

Chem Immunology (1998)

Chapter: T-Cell Receptor Usage in the Intestine

Ratings & Comments

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.

Ratings

Care provider's discussion of any proposed treatment (options, risks, benefits, etc.)

4.6

Likelihood of recommending this care provider to others

4.6

Explanations the care provider gave you about your problem or condition

4.6

Care provider's efforts to include you in decisions about your care

4.6

Concern the care provider showed for your questions or worries

4.7

Patient Comments

5.0

I have recommended Dr. Saubermann to people already

Mar 31, 2025

5.0

Dr Saubermann is always an excellent source of information and diet guidance.

Feb 02, 2025

4.8

Always positive

Dec 21, 2024

5.0

Happy with this team

Mar 01, 2024

5.0

As URMC is a teaching institution, I spent a good deal of time with the Fellow, who was very thorough. He then briefed Dr. Saubermann away from the examination room. They both rejoined me and answered my questions. I've participated in numerous clinical trials with Dr. Saubermann, so I trust him and respect his knowledge of both me and the field in general.

Jan 07, 2024

4.6

We discussed future treatment options and tests necessary to move forward to assess my condition. As well as coordinating with other doctors treating me for other things related to My overall health so they can coordinate together and work together as a team to assess my care and how to move forward with treatment.

Apr 21, 2023

5.0

He is a great doctor, overall.

Apr 10, 2023

3.0

I don't really feel listened to during my appointments here and I do not feel like I'm being taken care of.

Oct 28, 2022

5.0

Each visit has been helpful and compassionately managed.

Sep 30, 2022